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ABSTRACT
ABSTRACT
 Mast cell tumors represent the most common 
malignant skin tumor in the dog. This review outlines 
the incidence, etiology and clinical signs of mast cell 
tumors. Diagnostic tests, staging and treatments are also 
discussed. This study was performed by the Veterinary 
Oncology and Pathology of UNESP, Jaboticabal and the 
Service of Pathology Veterinary, of UNESP-Botucatu with 
the support of the Brazilian Association of Veterinary 
Oncology and the Brazilian Association of Veterinary 
Pathology. 
Key-words: canine, cutaneous neoplasm, diagnosis, 
prognosis, treatment.
Introduction 
 The cutaneous mast cell tumor (CMCT) is the third 
most common malignant cutaneous neoplasm in dogs, 
accounting for 11% of malignant skin tumors in dogs, 
being preceded only by lipoma and adenoma. Mast cell 
tumor (MCT) should always be considered in the list 
of differential diagnoses for a skin mass (London et al., 
2013). Based on these facts, studies of this neoplasm, as 
well as diagnostic, surgical and clinic approaches are of 
paramount importance to establish consistent predictive 
and prognostic criteria for patients.  
 This study was performed during the Consensus for 
the diagnosis, treatment and prognosis of CMCT in dogs, 
hosted by the Department of Veterinary Oncology and 
Pathology of UNESP, Jaboticabal and the Department 
of Pathology Veterinary, of UNESP-Botucatu with the 
support of the Brazilian Association of Veterinary 
Oncology and the Brazilian Association of Veterinary 
Pathology. 
 The purpose of this consensus was to discuss the criteria to 
guide diagnosis, prognosis and treatment of canine CMCT in Brazil. 
Veterinary oncologists, surgeons and pathologists from different 
regions of Brazil contributed to this consensus.
Incidence and Etiology 
 CMCT is recognized as one of the most common cutaneous 
tumors in dogs, however few studies have evaluated its national 
incidence. Studies in CMCT in Brazil reported the incidence 
between 20.9 and 22.4%, ranking it as the second most common 
malignant neoplasm in dogs, only after mammary tumors (De 
Nardi, 2002; Souza et al. 2006; Meirelles et al. 2010). Some breeds 
are predisposed to CMCT as Boxers, Golden Retrievers, Weimaraners 
and Dachshunds (De Nardi, 2002; Kiupel et al. 2005; Murphy et al. 
2006; Mullins et al. 2006; Costa-Casagrande et al. 2008; Furlani et al. 
2008). In a survey conducted of the archives of the Department of 
Animal Pathology, Department of Pathology, College of Veterinary 
Medicine and Animal Science, USP from 1993 to 2002, 126 mast 
cell tumor cases were diagnosed among 1813 neoplasm in dogs, 
accounting for 7% of all tumors analyzed. Boxer was the breed 
most commonly affected (Kimura et al. 2012).
 The etiology of MCT is not fully elucidated, Vail and Withrow 
(1996) proposed that it was associated with chronic inflammatory 
lesions and skin exposure to irritants, however current research 
has shown that mutations in the C-KIT gene contribute to the 
genesis of this  tumor. This gene, encodes the tyrosine kinase 
receptor of the stem cell factor (SCF also known as kit ligand, KL or 
steel factor) in neoplastic mast cells of dogs, and alterations in this 
gene develop uncontrolled growth of these cells and origin of the 
malignant tumor (London et al. 1999; Reguera et al. 2000; Zemke 
et al. 2002; Turin et al. 2006; Webster et al. 2007).
Clinical signs 
 MCT is presented as masses of different sizes and according 
to Hanh et al. (2004), tumors larger than 3 cm are associated with 
worse prognosis. In addition MCT can be well delimited, elevated, 
firm, pruriginous, may also show erythema or ulcerated surface, 
and subcutaneous tissue invasion may also occur (Daleck et al. 
2009). Some tumors are poorly circumscribed, elevated, soft and 
may not show erythema and ulceration, macroscopically very 
similar to cutaneous lipomas (Thamm and Vail, 2007; Daleck et 
al. 2009). The subcutaneous and CMCT presentations can be 
differentiated exclusively by histopathological analysis (Daleck 
et al. 2009). About 50% of the CMCT are reported in the trunk, 
perineal, genital and groin regions, 40% are in the limbs and 10% 
in the head and neck (Thamm and Vail 2007; Daleck et al. 2009).
 According to Couto (2006), the biological behavior of MCT 
is extremely variable. In general, well differentiated MCTs (grade I) 
have low metastatic potential. In contrast, tumors of grades 2 and 
3 commonly cause metastasis to regional lymph nodes and have 
high potential to spread, especially to the liver and spleen, while 
lung metastases are uncommon. Some researchers reported that 
mast cell tumors located in the oral cavity, nail bed or in the inguinal, 
perineal and preputial regions exhibit highly malignant behavior 
(Tams and Macy, 1981; Turrell et al. 1988; Fox, 1998; Couto, 2006). 
There is a study that states that there is no correlation between 
malignancy and location (Kiupel et al. 2005).
 CMCTs are typically solitary lesions, but their clinical 
appearance can be variable and some dogs can develop more than 
one apparently unrelated MCT. Studies suggest that multiple MCT 
should be treated as individual neoplasm, while prognosis should 
be related to each tumor characteristics and not to the number of 
tumors presented in the dog (Murphy et al. 2006). However, while 
O’Connell e Thompson (2013) demonstrated that multiple CMCT 
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lesions did not affect overall survival, Kiupel et al. (2005) 
reported a worse prognosis for patients presented with 
multiple lesions.
Paraneoplastic syndromes
 The clinical signs of MCT are present in up to 
half of dogs with mast cell tumor and include mast 
cell degranulation and release of histamine, heparin, 
chemotactic factor for eosinophils and proteolytic 
enzymes (Thamm and Vail 2007; Welle et al. 2008; Daleck 
et al. 2009). The effect of degranulation can be observed 
during patient physical examination by mechanical 
palpation of the tumor, resulting in erythema, wheal 
formation (Darier’s sign), edema, ulceration and swelling 
at the primary tumor site, and possibly delayed wound 
healing and local coagulation abnormalities (Thamm and 
Vail, 2007; Welle et al. 2008; Daleck et al. 2009; Blackwood 
et al., 2012).
 A major complication is gastrointestinal ulceration, 
affecting mainly the stomach and less frequently the 
duodenum. These lesions are usually multiple and 
superficial although in some situations perforations can 
be present. They occur due to increased histamine blood 
levels that stimulate the H2-receptor of parietal cells, 
therefore resulting in excessive production of gastric acid 
and increased gastric motility. Furthermore, histamine 
causes damage to the vascular endothelium of arterioles 
and venules and releases fibrolysin, leading to intravascular 
thrombosis and ischemic necrosis of the stomach mucosa. 
Heparin, in turn, tends to block the effects of histamine, 
but it is present in low concentrations in undifferentiated 
malignant mast cell tumors (Welle et al. 2008; Daleck et 
al. 2009; Blackwood et al., 2012). In such cases, clinical signs such as 
hematemesis, anorexia, hematochezia, melena, anemia, abdominal 
pain and in some cases intestinal perforation and peritonitis may 
be observed (Thamm and Vail, 2007; Welle et al. 2008; Daleck et 
al. 2009; Blackwood et al., 2012). According to Welle et al. (2008) 
gastrointestinal ulcers were observed in about 35 to 83% of dogs 
with mast cell tumors during necropsy examination.
 The delayed wound healing and dehiscence, observed 
after MCT surgical resection, are possibly related to the release of 
vasoactive amines and proteolytic enzymes by mast cells, which once 
bound to H1 and H2 receptors may lead to suppression of fibroblast 
growth factor reducing fibroplasia (Welle et al., 2008; Daleck et al., 
2009). Furthermore, local bleeding can also be observed during 
surgical resection, probably due to defective coagulation caused by 
release of heparin (Welle et al., 2008).
 Circulatory collapse, although rare, can occur in the presence 
of a massive release of histamine by neoplastic cells. Dogs with 
extensive disease are particularly at risk (Welle et al., 2008; 
Blackwood et al., 2012). 
Diagnostic approach
 The diagnostic evaluation of animals with suspected CMCT 
usually has three goals: 1) definitive diagnosis by cytological and 
histopathological examination; 2) clinical staging; 3) documentation 
of paraneoplastic syndromes. Immunohistochemical techniques 
have been applied to differentiate MCT from other anaplastic round 
cell tumors. MCT are vimentin positive and the majority is tryptase 
and CD117 (KIT) positive. Other markers like chymase, MCP-1 and 
IL-8 can be used (London and Thamm, 2013).
Cytology
 Fine needle aspiration (FNA) cytology gives a diagnosis 
for 92–96% of MCT. Mast cells quickly exfoliate and are easily 
identifiable by metachromatically staining intracytoplasmic 
granules but the grading cannot be established by cytology 
(Blackwood et al., 2012).
 Furthermore, the assessment of tumor grade in cytological 
smears does not allow following strictly the grade system 
proposed by Patnaik et al. (1984), since the evaluation of specific 
criteria, such as level of tissue invasion, cannot be determined by 
cytological examination.  The sample should be collected by fine 
needle aspiration (FNA) without aspiration. The needle chosen for 
the cytology should be 13x4.5mm (26G) in order to reduce blood 
contamination, thus increasing the accuracy of the diagnosis (De 
Nicola, 2009).
 Among round cell neoplasms, MCT has a characteristic 
morphology, as the presence of fine to coarse intracytoplasmic 
basophilic granules evidenced by the Romanowsky stains and their 
derivatives (De Nicola, 2009; Strefezzi et al. 2009; MacNeill, 2011; 
Grandi et al. 2014). Evaluation using Diff-Quik stain, commonly 
used in the routine, can be inconclusive since it may not stain 
mast cells granules (DeNicola, 2009; MacNeill, 2011). Regardless 
of the stain used, cells that constitute high grade tumors, may 
not exhibit abundant cytoplasmic granulation because they lose 
them during the differentiation process.  Strefezzi et al. (2009) 
demonstrated that nuclear morphometry could be associated 
with disease prognosis, showing a correlation between average 
nuclear area with survival time.
Camus et al. (2016) developed a cytologic grading scheme for 
canine MCTs, based on correlation with histologic grade, to predict 
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treatment planning and prognostication. The cytologic 
grading scheme classified a MCT as high grade if it was 
poorly granulated or had at least 2 of 4 findings: mitotic 
figures, binucleated or multinucleated cells, nuclear 
pleomorphism, or anisokaryosis (>50% variation in 
nuclear size) and the high tumor grade was also associated 
with increased probability of additional tumors or tumor 
regrowth. Other MCT markers such as CD25, interleukin-2 
receptor, c-kit mutations, and proliferation markers such 
as AgNOR and Ki67 complement cytologic and histologic 
grades may add additional prognostic information.
  However, Hergt et al. (2016) also proposed 
criteria to use a 2-tier histologic grading system on cytology 
specimens and concluded that cytologic grading of MCT 
in the dog is helpful for initial assessment, although, the 
reliability of cytology using the 2-tier grading system is 
considered inadequate at this point. Cytologic grading 
resulted in 36 high-grade and 105 low-grade tumors. 
Agreement between histologic and cytologic grading 
based on the 2-tier grading system was achieved in 133 
cases (sensitivity 86.8%, specificity 97.1%, kappa value 
0.853), but five high-grade tumors on histology were 
classified as low-grade on cytology.
In this consensus, we indicate that cytology should be 
used only for screening diagnosis, and the histopathology 
as definitive diagnosis and grading of canine MCT.
Histopathology 
Cutaneous mast cell tumor
 Histopathological grading is the primary tool to predict the 
biological behavior of cutaneous and subcutaneous MCT (Bostock, 
1973; Patnaik et al. 1984; Preziosi, Morini and Sarli, 2004; Kiupel et 
al. 2011; Thompson, 2011b). 
 The histopathological results depend on the adequate 
sampling of the material for diagnosis. Therefore, few 
recommendations on how the surgeon should send the sample for 
histopathologic analysis are described as follows: (1) corticosteroids 
or chemotherapy should not be used for tumor cytoreduction 
before the histopathological diagnosis; this will underestimate 
the assessment of cell proliferation index (mitotic index and 
immunohistochemical analysis with the antibody Ki67). When 
cytoreduction is necessary before the surgical procedure, it is 
recommended to perform a previous incisional biopsy in order to 
not compromise the evaluation of the proliferation index, and the 
referral form should specify whether this procedure was performed 
and the therapeutic protocol used for this purpose; (2) another 
possible option is excisional biopsy of the tumor with macroscopic 
safety margins of at least 3 cm whenever possible. This would enable 
the assessment of microscopic margins in greater detail, as well as 
the distinction between cutaneous and subcutaneous MCT, since 
these exhibit different behavior; (3) in cases of large tumors, when 
it is impossible to obtain clean margins, carefully perform incisional 
biopsy in order to avoid mast cell degranulation and risk to the 
patient; (4) immediately after biopsy, include a tumor sample in a 
10% formalin solution at a rate of 1:9  parts of tissue fixative for a 
maximum of 24 to 48 hours. Subsequently, transfer the tissue sample 
to a 70% alcohol solution. A prolonged formaldehyde fixation, as 
well as a short one, can impair the immunohistochemical staining 
and molecular biology analysis, prognostic and predictive values. 
 The large surgical pieces should be sectioned during the 
fixation in formaldehyde, for 24 to 48 hours, to obtain a minimum 
of four pieces per sample. The pieces should be identified with 
different Indian ink on the edges, for deep and lateral margins, 
or using suture stitches (Fulcher et al. 2006; Kamstock et al. 2011; 
Thompson, 2011a). Multiple nodules should be sent separately, 
and properly identified so histopathological analysis will be done 
individually for each node. The sentinel lymph node (SLN) should 
be referred and analyzed for the presence of metastasis. Samples 
of tumor and lymph node should be fixed with a maximum 
thickness of 1 cm2.
 For more details on how to submit surgical specimens, to 
identify the surgical margins and tumor sample processing, we 
recommend the article Recommended Guidelines for Submission, 
Trimming, Margin Evalu ation, and Reporting of Tumor Biopsy 
Specimens in Veterinary Surgical Pathology (Kamstock et al. 2011) 
 The grading system proposed by Patnaik et al. (1984) is 
the most widely used system for the classification of CMCT. 
According to this system, CMCT grade I consist of rows or clusters 
of monomorphic neoplastic mast cells well differentiated 
with rounded nuclei, small intracytoplasmic granules with cell 
proliferation confined to the dermis. CMCT grade I present rare 
mitotic figures, show no binucleate cells and may have minimal 
stromal reaction or necrosis. CMCTs grade II are moderately to 
markedly cellular, with moderately pleomorphic neoplastic mast 
cells, with round and/or pleomorphic nuclei and intracytoplasmic 
granulation of varying sizes. They extend into the deep dermis, 
subcutaneous tissue and occasionally deeper. MCT grade II have 
zero to two mitotic figures per high power field (HPF), discrete 
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areas of edema, necrosis and hyalinization of collagen. 
The grade III of CMCT are markedly cellular and composed 
of neoplastic mast cells with remarkable pleomorphism 
with rounded pleomorphic vesicular nuclei, containing 
multiple prominent nucleoli. The cells are arranged in 
dense sheets that replace the subcutaneous tissue and 
deep planes. Grade III mast cell tumors contain three to 
six mitotic figures per HPF, areas of hemorrhage, edema, 
necrosis and hyalinization of collagen. According to the 
original study, 94% of dogs with CMCT grade I survived 
more than 1500 days, compared with 56% of dogs with 
grade II and 7% of dogs with grade III.
 Although the Patnaik system is considered the 
“gold standard” for the prognosis of mast cell tumors, the 
prevalence of CMCT grade II and inter observer variability 
when grading the same tumor, reduce the accuracy 
of this classification system. Still, according to Patnaik 
criterion, for grade III mast cell tumors, specifically the 
high mitotic index (3-6 mitotic figures per HPF) excludes 
certain tumors with low proliferative index that could 
display aggressive biological behavior (Strefezzi, Xavier 
and Catão-Dias, 2003; Preziosi, Morini and Sarli, 2004; 
Northrup et al. 2005; Pinczowski et al. 2008; Strefezzi et al. 
2009; Kiupel et al. 2011).
 In order to decrease inter observer variability and 
have a more reliable histological classification, Kiupel 
et al. (2011) proposed another grading of CMCT. This 
histopathological classification is based on low and 
high grade of malignancy. At least one of the following 
characterizes CMCT of high malignancy: (1) at least seven 
mitotic figures counted in ten HPF, counted in areas 
of higher number of mitotic figures; (2) at least three 
multinucleated cells (three or more nuclei) in ten HPF; (3) at least 
three bizarre nuclei, markedly pleomorphic nuclei in ten HPF; or (4) 
karyomegaly (Kiupel et al. 2011; London e Thamm, 2013).
 In the study of Kiupel et al. (2011), three CMCT samples that 
were classified as high-grade malignancy did not have the seven 
mitotic figures counted in ten HPF, which indicates that the number 
of mitotic figures should not be the only criterion to classify high 
grade MCT. There was 100% agreement among pathologists in the 
grading of low and high malignancy MCT while according to this 
classification average survival time was less than four months and 
more than two years, respectively, for dogs with high and low-grade 
tumors (Kiupel et al. 2011).
  This consensus proposes that CMCT should be classified 
according to Patnaik et al. (1984) and Kiupel et al. (2011), including 
the histopathological diagnosis of the two grading systems (e.g., 
“CMCT grade III according to Patnaik and high-grade malignancy 
CMCT according to Kiupel”).
 Similarly, this item should also indicate the mitotic index (MI) 
in ten HPF, followed by MI reference. MI has been described as a 
prognostic factor independent of other histopathological features 
while higher mitotic rates are associated with a worse prognosis 
(Romansik et al. 2007; Elston et al. 2009). However, the cutoff values 
reported for the number of mitotic figures counted in ten HPF may 
vary from five to ten (Bostock, 1973; Romansik et al. 2007; Sueiro et 
al., 2007; Elston et al. 2009).
 Until further prospective studies define cutoff values 
statistically calculated for canine cutaneous mast cell tumors, the 
authors of this consensus recommend using the methodology of 
Romansik et al. (2007) ≤ 5 and> 5 mitotic figures or Elston et al. 
(2009) 0; 1-7 and> 7 mitotic figures, quoting the reference source 
in the report. Thus, as higher values of mitotic figures (>5 mitotic 
figures or >7 mitotic figures) are related to a worse prognosis, the 
use of chemotherapy in the postoperative period of some patients 
is recommended.
Subcutaneous mast cell tumors
 Many MCT arise in the dermis and extend to deeper levels, 
but there is a group of MCT that are confined to the subcutaneous 
adipose tissue and it seems that these tumors exhibit less aggressive 
biological behavior (Newman et al. 2007). Recently, a study of 306 
dogs categorized histopathologically the subcutaneous MCT and 
determined some prognostic markers for these tumors (Thompson 
et al. 2011a).
 Thompson et al. (2011a) classified the subcutaneous 
MCT in three patterns determined by light microscopy (4x): (1) 
circumscribed, (2) combined (infiltrative/circumscribed), and (3) 
infiltrative. In this study, the decreasing survival time was related 
to MI>4 ten HPF/40x and infiltrative histological pattern and the 
presence of multinucleated neoplastic mast cells.
Histochemistry
 Histochemical techniques like Giemsa, toluidine blue, 
Alcian Blue-Safranin are of utmost importance to establish the 
differential diagnosis with other round cell neoplasms and to 
identify intracytoplasmic granulation, especially in cases in which 
the cytoplasmic granules are scarce, thus facilitating visualization. 
Simões and Schoning (1994) compared various histochemical 
methods as hematoxylin-eosin and toluidine blue, Alcian blue, 
PAS, Giemsa, and others, commonly used to identify neoplastic 
canine mast cell with techniques of immunohistochemistry and 
lectin-histochemistry and found that, routine histochemical 
stains are efficient to mark intracytoplasmic granules of mast 
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cells. Difficulty remains in the undifferentiated mast cells, 
which only were identified with higher frequency by 
immunohistochemistry technique in this study.
Although AgNOR count is strongly correlated with tumor 
grading and this method can provide greater objectivity 
to the classification of Patnaik et al. (1984), the consensus 
established that mast cell AgNOR staining should not 
be adopted in routine due to the lack of standardization 
and interpretation of the technique. Instead, only 
immunohistochemistry technique should be used to 
determine cell proliferation using Ki-67 antibody.
Immunohistochemistry analyses
 There are numerous studies using 
immunohistochemistry to analyze immune markers that 
help understand the biological behavior of MCT. However, 
few antibodies have real predictive and prognostic value 
(Kamstock et al. 2011).
 The antibodies that best characterize the 
aggressiveness and malignant potential of cutaneous and 
subcutaneous MCT are the Ki-67 (proliferation index) and 
KIT (membrane receptor for stem cell factor) (Abadie et al., 
1999; Preziosi, Morini and Sarli, 2004; Webster et al., 2004; 
Scase et al., 2006 Webster et al., 2007; Maglennon et al., 
2008; Strefezzi et al., 2010).
 The methods used to calculate the proliferation 
index vary considerably between studies (Abadie et al. 
1999; Scase et al. 2006; Webster et al. 2007; Maglennon 
et al. 2008; Strefezzi et al. 2010). There is inter observer 
variability while examining different tumor areas and 
total fields on a slide, as well as different techniques used in 
immunohistochemistry for the same antibody.
 Therefore, we recommend the methodology proposed 
by Webster et al. (2007) for cell proliferation using the Ki-67 
immunostaining for CMCT and the method of Thompson et al. 
(2011b) for subcutaneous MCT. For CMCT, Ki-67> 23 positive cells/5 
HPF is associated with high risk of recurrence and/or metastasis 
(Webster et al. 2007).
 Studies have determined expression patterns of KIT protein 
in CMCT (Preziosi, Morini and Sarli, 2004; Webster et al. 2004). 
Three localization patterns of the KIT protein were identified, 
namely membranous (KIT pattern 1), focal cytoplasmic with loss 
of membrane labeling (KIT pattern 2) and diffuse cytoplasmic 
(KIT pattern 3). These patterns were associated with tumor 
aggressiveness showing that focal and diffuse cytoplasmic patterns 
had an unfavorable prognosis (KIT patterns 2 and 3) (Webster et 
al. 2004). It is indicated that immunohistochemistry reports use 
the nomenclature adopted by Webster et al. (2004) for the c-KIT 
patterns in order to create a single and standard report.
Molecular biology for gene C-KIT
 In 1999, two studies described the presence of mutations 
in the C-KIT gene in canine MCT (London et al. 1999; Ma, Longley 
and Wang, 1999).  KIT is a membrane receptor with tyrosine kinase 
activity for stem cell factor (SCF), which stimulates mast cell growth. 
These two studies described duplication of DNA in the C-KIT gene, 
called internal tandem duplications (ITDs). These mutations were 
found in exons 11 and 12 of the gene.
 When the SCF binds to the KIT receptor without 
mutation, the cytoplasmic portion of the receptor undergoes 
autophosphorylation. In the presence of ITD in exon 11, the receptor 
is constitutively phosphorylated, regardless of SCF presence. This 
KIT phosphorylation activates signaling pathways that stimulate 
the growth of neoplastic mast cells (London et al. 1999).
 Therefore, the presence of this mutation is directly responsible 
for the uncontrolled proliferation of the tumor, which in this case 
carries a poorer prognosis (Webster et al. 2007). The discovery of 
an aggressive behavior of MCT by a constitutive activation and 
signaling of a tyrosine kinase receptor, result in research about 
the use of tyrosine kinase inhibitors in MCTs (London et al. 2009; 
Yamada et al. 2011).
 After a decade of research in canine populations, the ITD 
mutation was found in approximately 30% of cutaneous MCT. Other 
mutations, deletions and insertions have also been found in this 
tumor, but rarely observed (Ma, Longley and Wang, 1999; London 
et al. 1999; Downing et al. 2002; Zemke et al. 2002; Reguera, Ferrer 
and Rabanal, 2002; Jones et al. 2004; Riva et al. 2005; Webster et al. 
2006a; Webster et al. 2006b; Webster et al. 2007; Letard et al. 2008; 
Ohmori et al. 2008; London et al. 2009). Only one study examined 
the presence of mutation in the C-KIT gene in subcutaneous MCT; 
and it was absent in all cases (n = 60) (Thompson et al. 2011a).
 The test to detect C-KIT mutation is routine because the 
result can guide therapeutic choices. Several laboratories offer 
C-KIT mutation analysis, most commonly for exon 11 ITD since 
alterations in other exons are not commonly reported (Avery, 
2012).
 The PCR test is performed on samples embedded in paraffin, 
of which the genomic DNA of tumor cells is extracted. PCR using 
specific primers amplify the gene segment where the mutations 
is most commonly inserted (e.g., exon 11) and the products are 
separated by gel electrophoresis (Jones et al. 2004). Jones et al. 
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(2004) demonstrated the efficacy of the method when 
compared to other types of development and highlighted 
that the incidence of punctual/small mutations is very 
rare in canine MCT, which avoids the use of sequencing 
as a diagnostic method. Positive control may not be used 
reliably as a control method due to different mutation 
patterns (duplicates, deletions and insertions). It is 
recommended to use a standard molecular weight control, 
so the reaction control is warranted and optimizes the 
identification of different types of changes that may arise 
in the interpretation of the PCR results. 
 Analyses of mutation to the gene C-KIT should be 
included in a panel of markers for mast cell tumors, since 
they have prognostic and predictive value (Avery, 2012). 
These tests must discriminate which mutation, deletion, 
or insertion polymorphisms should be searched, since 
many of them do not lead to constitutive phosphorylation 
of the C-KIT gene (Webster et al. 2007; Létard et al. 2008; 
Yamada et al. 2011; Avery, 2012).
Staging
 Staging must be performed to define the extension 
of the disease since it greatly influences the therapeutic 
choice, and also the prognosis (Daleck et al. 2009; London 
e Thamm, 2013). Current staging of MCTs practiced 
by many veterinarians involves a minimum of lymph 
node assessment, abdominal ultrasound and thoracic 
radiography; however, Warland et al. (2012) concluded 
that thoracic radiography was not useful in the staging 
of canine MCT. The World Health Organization (WHO) 
has proposed a clinical staging system for canine MCT; 
however, several studies have questioned its use, especially 
for MCT grade III (Murphy et al. 2006; Thamm and Vail, 2007; Daleck 
et al. 2009). Because of this, the authors of this consensus propose 
to adopt the staging system described at the Southern European 
Veterinary Conference (SEVC) in Barcelona 2008 (Table 1).
Table 1 – Clinical Staging System for Canine Mast Cell Tumor
Stage Tumor R e g i o n a l 
l y m p h 
nodes
Metastasis
I Single, <3cm, well-
circumscribed
- -
II +1 node, <3cm,  interlesional 
distance>10cm, well-
circumscribed
- -
III 1 or +, >3cm,  interlesional 
distance <10cm, poorly 
circumscribed or ulcerated
- -
IV Any lesion type + -
V Any lesion type - or + +
Suffixes a: without systemic signs, b: with systemic signs.
 MCT usually metastasizes to lymph nodes (LN), spleen and 
liver. Lung involvement is infrequent, bone marrow and peripheral 
blood in systemic dissemination may be compromised (London e 
Thamm, 2013).  
 Warland et al. (2012) found in their study that no tumors spread 
distantly metastasis without first showing local LN metastasis. For 
this reason, the authors suggest that the local LN is sentinel to the 
evaluation of metastasis of MCT. Histological examination of these 
LNs provides information on the status of lymphatic metastasis 
for the entire lymphatic system. However, abdominal organs were 
not aspirated unless ultrasonographic abnormalities were found. Is 
important to say that not all local LNs are possible to palpate and 
collect FNA, like iliac LN. In the same study, 30.9% of tumors had 
metastasized at presentation; similar to another study did by Krick 
et al. (2009). 
Radiography and ultrasonography are widely used as a screening 
tool. However, Book et al. (2011) showed that ultrasonography 
sensitivity to detect spleen and liver metastasis is 43% and 0%, 
respectively, which suggests that FNA or ultrasound guided 
biopsy should be performed in all cases of CMCT regardless of 
ultrasonographic findings. Krick et al. (2009) demonstrated that 
cytological evaluation of lymph nodes of dogs with MCT provides 
valuable clinical information and correlates with tumor grade 
and prognosis, in addition of being a practical and non-invasive 
technique. Dogs with positive cytological evidence of infiltration 
by mast cells in the spleen, liver, or both, have a worse prognosis 
(Book et al. 2011).
Hume et al. (2011) conducted a retrospective study in dogs with 
MCT grade III and described higher survival time in patients without 
lymph node metastasis at the time of diagnosis, when compared 
to dogs with positive lymph node metastasis. Therefore, lymph 
node metastasis constitutes an important prognostic factor and 
should be treated accordingly. Dogs with positive lymph node 
metastasis treated with surgery or radiation therapy had a mean 
survival of 240 days, whereas untreated dogs had 42 days.
The SLNs are important in the staging of several types of human 
cancer, providing information as prognosis and treatment strategy 
in these cases. In veterinary medicine the assessment of the SLN 
during the staging should be incorporated, especially in breast 
cancer, osteosarcoma, synovial sarcomas and MCT (Tuohy et al. 
2009). Therefore, we recommend FNA and cytologic evaluation 
of regional lymph nodes or SLN, for metastasis evaluation prior to 
wide surgical excision (London e Thamm, 2013).
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Treatment
Surgery
The main treatment of canine MCT is surgical resection. 
Whenever possible, a 3 cm for lateral and one fascial layer 
for deep margins of the lesion should be considered. 
Moreover, the removal of the fascia musculature and 
muscle is indicated to remove the tumor as a block (Daleck 
et al. 2009; MacPhail, 2014).
It is necessary to avoid manipulation of the lesion during 
the procedure to prevent mast cell degranulation and 
systemic adverse effects on the patient (MacPhail, 
2014). It is further recommended that SLN are removed 
intraoperatively. In cases of tumor removal prior to lymph 
node, surgeons should replace all the material and surgical 
fields (Hume et al. 2011).
 When the lesion is present in the scrotum, it is 
recommended to perform scrotal ablation and orchiectomy. 
If the prepuce is also compromised, penectomy associated 
with scrotal urethrostomy should be indicated (MacPhail, 
2014). In the limbs, reconstructive techiniques as pedicled 
or bi-pedicled, tubular or hinge flaps are the best forms of 
surgical correction in order to preserve the limb. However, 
amputation of the compromised limb is more appropriate, 
but this technique is not always accepted by the owners 
due to the cosmetic appearance of the patient (MacPhail, 
2014; Daleck et al. 2009).
 Healing by second intentions is recommended 
when it is not possible to use reconstructive techniques or 
appropriate sutures that promote tissue closing. It is preferable to 
have a postoperative open wound, which heals secondarily than the 
occurrence of compromised margins (Daleck et al. 2009; MacPhail, 
2014).
Antineoplastic chemotherapy
Antineoplastic chemotherapy is an important technique to treat 
unresectable tumors, in the postoperative of high grade and grade 
III mast cell tumors and, when surgical margins are compromised 
by neoplastic cells (Welle et al. 2008). In addition, chemotherapy 
is indicated in cases of advanced clinical staging to downstage the 
tumor for subsequent surgery (Daleck et al. 2009).
Neoadjuvant chemotherapy main objective is to promote 
cytoreduction in cases of difficult surgical resection. The protocols 
more commonly used are lomustine as a single agent at a dose 
of 60 to 90mg/m2, every 21 days, for a total of 2 sessions or, 
vinblastine associated with prednisone, according the protocols in 
Table 2. It is important to say that cytoreduction using neoadjuvant 
chemotherapy usually has a temporary response lasting an average 
40-70 days, so surgical procedure is indicated during this period 
(Rodasky and De Nardi 2008; Daleck et al. 2009).
 In most studies, vinblastine is used to treat MCTs at a dose of 
2.0mg/m2 every 1 or 2 weeks, associated or not with prednisone 
(Table 2) (Davies et al. 2004; Trumel et al. 2005; Thamm, Turek and 
Vail, 2006; Hayes et al. 2007). In dogs, dose limiting is characterized 
by neutropenia (Golden and Langstin, 1988; Davies et al. 2004; 
Trumel et al. 2005; Thamm, Turek and Vail, 2006). Vinblastine nadir 
is observed approximately 7 days after administration (Rosenthal, 
1981). In order to improve treatment effectiveness, some studies 
suggest gradual increase of dosage to 2.33, 2.67 and 3mg/m2 
weekly (Vickery et al. 2008; Rassnick et al. 2008). Vinblastine can 
be safely administered in dose of 3.00mg/m2, above this level 
some hematological and gastrointestinal effects may be observed 
(Vickery et al. 2008; Rassnick et al. 2008). The highest tolerated dose 
is 3.5mg/m2 every two weeks (Bailey et al. 2008). The authors of 
this consensus recommend the use of vinblastine associated with 
prednisone as the first option of treatment, in the postoperative 
of high grade and MCT grade III, and when surgical margins are 
compromised. When the response is not positive with the use of 
these drugs, we suggested the use of lomustine 70 to 90mg / m2.
Table 2– Chemotherapy protocol of vinblastine and prednisone to 
treat MCT in dogs.
Week Vinblastine (2mg/
m2)
Prednisone
1st X X  (1 mg/ kg)
2nd X X  (1 mg/ kg)
3rd X
4th X
5th
6th X
7th X (0.5 mg/ kg)
8th X
9th
10th X
11th
12th X
Multidrug protocols have promoted higher response when 
compared to single agent chemotherapy (partial response) 
(Govier, 2003). Thus, numerous chemotherapy protocols have been 
described in the literature (Table 3); however, there is little data 
regarding disease-free interval and other important criteria that 
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allow compare different protocols (Taylor et al. 2009). It is 
known that MCT have different response rates to different 
chemotherapy protocols and the occurrence of adverse 
effects may be common among patients (Webster et al. 
2008).
Table3 -Published chemotherapy protocols to treat 
advanced MCT in dogs and remission rates (RR) (Adapted 
from Taylor et al. 2009).
C h e m o t h e r a p y 
Protocol
n n (DGI) RR (C+P)
Prednisolone 25 25 20%
Prednisolone and 
vinblastine
41 28 47%
P r e d n i s o l o n e , 
vinblastine and 
cyclophosphamide
35 11 63%
Lomustine 19 19 40%
Chlorambucil and 
prednisolone
21 21 38%
n= total number of animals
n(DGI)=total number of dogs gravely ill  (Patients severely 
compromised by disease progression) 
RR= remission rate (C= complete) and (P= partial)
Taylor et al. (2009) treated 21 dogs with unresectable MCT 
grade II and III with a combination of prednisolone 40mg/
m2 orally SID for 14 days and 20mg/m2 EOD thereafter, and 
chlorambucil 5mg/m2 orally SID. In cases when complete 
remission was achieved, treatment was discontinued after 
six months, if not, treatment was continued.  Three dogs 
achieved complete remission; nine in stable disease, five in partial 
remission and four in disease progression (overall response rate 
38%). According to the authors, the study showed poorer response 
when compared to other protocols.
Hosoya et al. (2009) used lomustine (60 mg/m2 every three weeks) 
and prednisone (40mg/m2 SID, for seven days, followed by 20mg/
m2 EOD) in partially resected MCT grade II. The animals received 
treatment for four to six months. In this study, no animals developed 
local recurrence and regional or distant metastasis. Furthermore, 
100% of animals were disease free at one year interval and 77% at 
two years interval.
Hayes et al. (2007) evaluated prednisolone (1mg/kg) and vinblastine 
(2mg/m2, about eight doses for each patient) in dogs with CMCT 
grade III after surgical resection. In this study, the animals without 
lymph node metastasis had a survival time of 800 days. In contrast, 
dogs with lymph node metastasis lived an average of 481 days 
after diagnosis. Furthermore, Wesbter et al. (2008) found that 
treatment with vinblastine (2mg/m2 once per week for four weeks) 
and prednisone (2mg/kg orally daily) after surgery was beneficial 
to dogs with MCT grade III when compared to those only treated 
with surgery. Thus, according to the authors, the results of this 
study validate the use of adjuvant vinblastine and prednisolone. In 
addition, dogs with c-KIT mutation treated with this protocol had 
longer disease-free interval and survival. In contrast,  Rungsipipat 
et al. (2009) observed a partial response rate of 78.2% in dogs with 
CMCT grade III  that were treated with adjuvant vinblastine (2mg/
m2 at weeks one, two, three, four, six, eight, ten and twelve) and 
prednisolone (1mg/kg, for four weeks, after 0.5 mg/kg for eight 
weeks).
Cooper, Tsai and Bennet (2009) evaluated the effect in dogs with 
grade II and III CMCT of chemotherapy with lomustine (60mg/m2) 
and vinblastine (2mg/m2), divided into two groups - macroscopic 
and microscopic disease. The authors showed that this protocol was 
well-tolerated and suitable for disease control since the response 
lasted longer compared to other agents.
Rassnick et al. (2010) evaluated the protocol with lomustine (70mg/
m2), vinblastine (3.5mg/m2) and prednisone (1-2mg/kg). A total of 
17 dogs had unresectable MCT. The response rate in animals that 
did not undergo surgery was 65% (five with complete remission 
and six with partial remission).
To date, few studies have been published involving the mechanisms 
of multi-drug resistance (MDR) in canine MCT. Despite the expression 
by different methods of detection of key genes and proteins involved 
in MDR in MCT (MDR1, P-glycoprotein, Glutathione-S-transferase pi, 
protein associated with multidrug resistance 1, p53, etc.)  no studies 
have confirmed the exact mechanism involved in chemotherapy 
resistance. Apparently, there is no histological association with the 
expression of MDR mechanisms that could justify the reasons why 
undifferentiated tumors respond unsatisfactorily to chemotherapy 
(Ginn et al. 2000; Jaffe et al. 2000; Miyoshi et al. 2002; Nakaichi et 
al. 2007).
The use of glucocorticoids as the sole treatment of canine MCT 
remains controversial regarding the induction of MDR. Recently, 
Teng et al. (2012) evaluated prednisone as the sole treatment of 
CMCT. These authors found that prednisolone caused a significant 
reduction in tumor size although it promotes gradually resistance 
since response rate was short (81.5% of patients showed maximal 
response for three weeks). The majority of MCTs overexpressed both 
P-glycoprotein and signal transducer and activator of transcription 
3 (STAT3) before and after prednisolone treatment. 
Previously, Matsuda et al. (2011) showed that the sensitivity in vivo 
and in vitro of canine MCT to glucocorticoids (GC) is associated 
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with the expression of the glucocorticoid receptor (GR) in 
neoplastic mast cells; however, there was a great difference 
in sensitivity to GC among the various MCTs and MCT cell 
lines. The degree of GC resistance was inversely correlated 
with GR expression. Interestingly, this study did not find 
a relationship between GC sensitivity and pathological 
grade of the MCT and neither between breed of dog 
and GR expression.  Overexpression of MDR1 has been 
known to be involved in drug resistance in many tumors, 
however, this study also showed that the high expression 
of MDR1 was not evident in any of the canine MCT cell 
lines used. The authors suggested that the detection of 
the expression of GR can be useful for predicting mast cell 
tumor sensitivity to glucocorticoids.
The metronomic chemotherapy regimen has been studied 
with primary results so far (Colleoni et al. 2002; Pasquier et 
al. 2010). For example, chlorambucil metronomic regimen 
(4mg/m2/day/35 weeks) resulted in complete regression 
of MCT in a dog (Leach et al. 2012).
Electrochemotherapy
The electrochemotherapy (ECT) has emerged as a feasible 
technique to treat superficial and mucosa tumors since 
the 1990s (Mir et al. 1991). It associates electroporation 
with chemotherapy to boost cytotoxic effect of the drug 
(Mir et al. 1998).
 Kodre et al. (2009) reported ECT as single therapy to treat 
CMCT and showed recovery rates similar to those obtained 
after surgical excision without associated chemotherapy 
and lesion regression for 31.5 months average. Spugnini 
et al (2006) treated dogs with incomplete surgical margins and 
found that in 85% of cases the average recurrence rate was 52.7 
months. 
Adverse effects such as degranulation were reported in two cases 
out of 28 (Spugnini et al. 2006). Kodre et al. (2009) stated that due 
to the vasoconstriction caused by ECT no mast cell degranulation 
occurs and they did not observe this adverse effect in 12 treated 
patients. The median size of the tumors treated by ECT in this study 
was 2.9 cm3. These authors also concluded that ECT is an easy, 
effective and safe local treatment of MCT and can be an alternative 
treatment to surgery, specifically for smaller nodules in which a 
complete response with long duration can be obtained after only 
one treatment session, or when the nodule is unresectable because 
of the location.
Tyrosine kinase receptor inhibitors
Tyrosine kinase inhibitors (TKI) may be used in cases of unresectable 
or recurrent MCT where conventional therapy is not appropriate 
or available (Blackwood et al. 2012). Besides being involved in the 
normal cell cycle, studies suggest that tyrosine kinase receptors 
have a key role in the neoplastic process. Overexpression of these 
receptors and mutations in proto-oncogenes that encode these 
receptors cause uncontrolled cell proliferation that leads to tumor 
development (London, 2009). In addition, these receptors are 
involved in angiogenesis, which is important for the nutrition of 
malignant cells and a route for dissemination of metastasis (Thurson 
et al. 2004).
The participation of the receptor tyrosine kinase KIT in mast cell 
represents one of the greatest examples of the action of these 
receptors in the development of malignancies in dogs (London, 
2009). After its discovery in carcinogenesis, a large effort has been 
directed at the development of strategies to inhibit its function in 
cancer cells and angiogenesis (Argyle, 2007).
The major strategy developed in veterinary medicine in order to 
inhibit these receptors was the use of so-called “small molecule 
kinase inhibitors tyrosine”. These act by blocking ATP from bind 
to the receptor by a competitive inhibition mechanism (reversible 
or not) preventing the phosphorylation and signals of cell 
proliferation and angiogenesis (London, 2009). 
The tyrosine kinase inhibitors currently available for the treatment 
of MCT in dogs are Toceranib (Palladia®), Masitinib (Kinavet®/
Masivet®) and Imatinib (Gleevec®). The option of using this type 
of therapy in this tumor must be assessed following the clinical 
indications of drugs, such as the presence of C-KIT mutation, 
evaluated by molecular analysis as previously discussed, along 
with immunohistochemical findings of expression patterns of 
the KIT protein. According to the authors the treatment with the 
tyrosine kinase inhibitor should be instituted for patients with 
C-KIT mutation and patients with KIT pattern 2 and KIT pattern 
3 in the immunohistochemistry analysis as discussed previously. 
However, there is no evidence that MCTs with standard KIT pattern 
2 or 3 respond to treatment in the same way as mastocytes with 
C-KIT gene mutation.
Dogs with MCT that do not have C-KIT mutation can also benefit 
from TKI due to the antiangiogenic effect achieved by inhibition 
of vascular endothelial growth factor (VEGF) and platelet derived 
growth factor (PDGF), but in these cases the response to therapy 
is generally lower. Currently, TKI are indicated in many other 
circumstances like multiple drug resistant, unresectable tumors, 
grade II and III, presence of metastasis and as rescue therapy in 
recurrent tumors (London et al. 2009; Soria et al. 2009; Ogilvie and 
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Ahn, 2010; Hahn et al. 2010, Phillips et al. 2010; Macedo 
et al. 2012).
Recommended doses for TKI are: Imatinib 5 to 10 mg/
kg/ VO/SID, Masitinib 12.5 mg/kg/VO/ SID and Toceranib 
3.25 mg/kg/VO/ EOD or Monday-Wednesday-Friday 
scheme. The literature indicates that these drugs should 
be administered continuously lifelong (London, 2009). 
The authors of this consensus recommend the use of 
Masitinib 12.5 mg/kg, VO, SID as a treatment for MCTs with 
a mutation in the C-KIT gene and for chemoresistance over 
six months. After this period the dose may be reduced to 
6.25 mg/kg, VO, SID, throughout life.
Similar to what happens with chemotherapeutic agents; 
TKI also have side effects (London et al., 2009). These 
effects result from the chronic inhibition of the tyrosine 
kinase receptor in normal cells, which depend on these 
for survival and proliferation in normal conditions. 
The main side effects are gastrointestinal issues and 
neutropenia, but signs of hepatotoxicity, nephrotoxicity, 
hypoalbuminemia and hypertension have also been 
reported (London, 2009).
Radiotherapy
 Radiation therapy in dogs with MCT can be 
performed prior to surgery, post-operative or palliative 
(only to pain control) (Dobson and Scase, 2007). In cases 
where the diffuse and/or extensive nature of tumor mass 
prevents surgery, radiotherapy should be taken into 
consideration, although studies on the use of radiation as 
a single therapy to treat canine MCT are scarce (Dobson, Cohen and 
Gould, 2004).
Adjuvant radiotherapy to treat MCT grade II when complete 
surgical resection was not possible, showed 12 months of disease-
free survival in 94-97% of cases (Al-Sarraf et al. 1996; Frimberger et 
al. 1997; Ladue et al. 1998). The use of this therapy in incompletely 
excised MCT grade III was also indicated for tumor management 
(Hahn, King and Carreras, 2004). MCT located in head and distal 
region of limbs are important examples of difficult complete removal 
of tumors while preserving local anatomy; therefore, radiotherapy 
is recommended (Dobson, Cohen and Gould, 2004).
The tumor response to radiation is dose-dependent. An increased 
dose can lead to a significant increase in tumor response. 
Furthermore, a study performed to determine the optimal dose 
(maximum effect on the tumor and minimal toxicity to healthy 
tissues), used small radiation fractions (4x 800 cGy) in 7 day intervals 
to treat dogs with different grades of unresectable MCT, reported 
85% partial or complete response rate (Dobson, Cohen and Gould, 
2004). In another study, radiotherapy protocol was three sessions 
(54 Gy) per week and showed remission response of 94% in one 
year and 88% in five years (Al-Sarraf et al. 1996). For better results 
regarding disease-free periods, irradiation is recommended directly 
on the tumor and regional lymph nodes (Dobson, Cohen and Gould, 
2004).
In a weekly radiotherapy study, many animals developed mild 
erythema in the treated area without sever signs related to 
degranulation and histamine release. Alopecia, hyperpigmentation 
and thickening of the skin in the affected area were also observed 
as late effect (Dobson, Cohen and Gould, 2004).
La Due et al. (1998) evaluated the effectiveness of megavoltage 
radiation therapy to treat 56 dogs. Radiation treatment length 
ranged from 14 to 28 days. The average disease-free interval was 
32.7 months, 15 months for dogs older than 7.5 years and 62 
months for dogs younger than 7.5 years. The data presented in the 
paper show that megavoltage beam radiation is effective to treat 
mast cell tumors.
Carlsten et al. (2012) performed a multicenter prospective trial with 
a combination of hypofractionated radiation treatment, Toceranib, 
and prednisone for measurable canine MCT and they concluded 
that this protocols is a viable treatment option for unresectable 
MCTs, well tolerated and efficacious in the majority of dogs and 
that the response rates and durations were higher than those 
reported for Toceranib as a single-agent treatment for MCT. 
Prognosis
The biological behavior of canine MCT varies widely from low 
metastatic potential to extremely aggressive lesions, leading 
to metastasis and death. Several prognostic factors of MCT 
in dogs such as clinical staging, tumor growth rate, breed 
predisposition, systemic signs, recurrence, patient age, tumor size, 
histopathological grade, mitotic index, proliferation index Ki-67 
and Kit immunostaining pattern were discussed in the text and 
are shown in Table 4. These factors can be used in an attempt to 
predict tumor biological behavior, as well as to direct the treatment 
(London and Seguin, 2003).
Table 4 - Prognostic factors for cutaneous mast cell tumors in dogs
investigação, 17(1): 01-15 2018
ISSN 21774780
12
PROGNOSTIC FACTOR NEGATIVE POSITIVE AUTHOR
Tumor size >3 cm < 3 cm Hanh et al. 2004
Tumor site* Perineum, prepuce, 
inguinal region, paws, 
head, limb, foot
Other sites Gieger et al. 2003;
Couto et al. 2006; Hanh 
et al. 2008; Warland et 
al. 2012
Number of tumors* Multiple tumors Single tumor Kiupel et al. 2005
Metastasis Present Absent Hume et al. 2011; Book 
et al. 2011; Warland et 
al. 2012
Surgical margin* Compromised margin Free margins Ozaki et al. 2007
Mitotic Index** >5 < 5 Romamsik et al. 2007;
Nuclear Morphometry in 
Cytology (Papanicolaou)
nuclear area≥62,39µm2 Nuclear area 
<62,39µm2
Strefezzi, Xavier and 
Catão-Dias, 2003
KIT pattern
immunostain
KIT 2 e 3 KIT 1 Kiupel et al. 2004
Mutation of the gene c-KIT Present Absent Webster et al. 2006
Ki – 67 Index >23 <23 Webster et al. 2007
Tumor
intravascular density
>14.1 mm-2 <14.1 mm-2 Preziosi, Morini and 
Sarli,2004
*There is no consensus among all authors that tumor site, presence of multiple tumors or 
compromised margins are associated with a worse prognosis.
** Some authors suggest as cutoff value for the mitotic index > or < than 7 (Elston et al. 2009).
 
Future Perspectives
Researchers have tried to find new strategies for the treatment of MCT in dogs. A recent genetic 
study evaluates the effectiveness of intramuscular or intra tumoral therapy using eletrogene 
with interleukin-12 encoding plasmid (IL-12). These treatments resulted in complete 
remission in two out of three dogs with MCT and a reduction in volume in up to 83% of the 
tumors (Pavlin et al. 2011).
Advances in epigenetics show the existence of hypoacetylation of histones in cancer. With 
this, the experimental treatments with an inhibitor of histone deacetylation, AR-42, induced 
reduction in growth and apoptosis “in vitro” in a strain of canine MCT, proving to be a promising 
therapy for this tumor (Lin et al. 2010). A Brazilian study evaluated the Trichostatin A (TSA), 
an inhibitor of histone deacetylase that has antiproliferative effects and induces apoptosis 
in cancer cells. The action of the drug “in vitro” in MCT grade III cells showed deleterious 
effects on the growth and proliferation of tumor cells, suggesting a good chemotherapeutic 
potential (Nagamine et al. 2011).
Final Comments
According to the available literature, we suggest:
• Cytological analysis only as a diagnostic screening;
• Histopathological examination to confirm the cytologic diagnosis, tumor grade (using 
the classifications proposed by Patnaik et al. 1984 and Kiupel et al. 2011)  and assessment of 
surgical margins; 
• Use of the mitotic index as an aid in determining prognosis;
• Staging must be performed to define the extent of disease since it greatly influences 
the therapeutic choice and prognosis;
• Treatment based not only on grade system but also on clinical signs, histopathologic 
and immunohistochemical findings.
• Chemotherapy as neoadjuvant and adjuvant therapy
• Tyrosine kinase inhibitor should be instituted for patients with C-KIT mutation and 
patients with  KIT pattern 2 and KIT pattern 3 in the immunohistochemistry analysis
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